About us Contacts Drug interactions: 390 212
Drug search by name

Polatuzumab Vedotin-piiq and Seconal

Determining the interaction of Polatuzumab Vedotin-piiq and Seconal and the possibility of their joint administration.

Check result:
Polatuzumab Vedotin-piiq <> Seconal
Relevance: 09.07.2023 Reviewer: Shkutko P.M., M.D., in

In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.

Consumer:

Consumer information for this interaction is not currently available.MONITOR: Coadministration with inducers of CYP450 3A4 may decrease exposure to unconjugated monomethyl auristatin E (MMAE), the anti-mitotic and cytotoxic component of polatuzumab vedotin. MMAE is a substrate for CYP450 3A4. Concomitant use of polatuzumab vedotin with rifampin, a potent CYP450 3A4 inducer, is predicted to decrease unconjugated MMAE exposure (AUC) by 63% according to the product labeling. No data are available for other, less potent CYP450 3A4 inducers. MANAGEMENT: The potential for diminished pharmacologic effects of polatuzumab vedotin should be considered during coadministration with CYP450 3A4 inducers. Alternative treatments may be required if an interaction is suspected. References "Product Information. Polivy (polatuzumab vedotin)." Genentech, South San Francisco, CA.

Professional:

MONITOR: Coadministration with inducers of CYP450 3A4 may decrease exposure to unconjugated monomethyl auristatin E (MMAE), the anti-mitotic and cytotoxic component of polatuzumab vedotin. MMAE is a substrate for CYP450 3A4. Concomitant use of polatuzumab vedotin with rifampin, a potent CYP450 3A4 inducer, is predicted to decrease unconjugated MMAE exposure (AUC) by 63% according to the product labeling. No data are available for other, less potent CYP450 3A4 inducers.

MANAGEMENT: The potential for diminished pharmacologic effects of polatuzumab vedotin should be considered during coadministration with CYP450 3A4 inducers. Alternative treatments may be required if an interaction is suspected.

References
  • "Product Information. Polivy (polatuzumab vedotin)." Genentech, South San Francisco, CA.
Polatuzumab Vedotin-piiq

Generic Name: polatuzumab vedotin

Brand name: Polivy

Synonyms: Polatuzumab vedotin, Polatuzumab Vedotin

Seconal

Generic Name: secobarbital

Brand name: Seconal, Seconal Sodium

Synonyms: n.a.

In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.

Interaction with food and lifestyle
Disease interaction